Data from EMC - Curated by Toby Galbraith - Last updated 19 May 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal


Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)


Related Content

More information

Category Value
Agency product number EMEA/H/C/003825
Orphan designation No
Date First Approved 18-02-2016
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Bayer Pharma AG
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions